reported that compared to the HER2-negative BC stem cells, HER2+/CD44+/CD24−/low cells showed a more aggressive phenotype and in vivo tumorigenesis with an enhanced resistance to radiation, indicating that HER2-expressing breast cancer stem cells (BCSCs) may be effective targets for the treatment of recurrent tumors (72). This evidence concerns the gene CD44 and breast cancer.